In a phase 3 randomized clinical trial involving 410 people with early Parkinson disease, 52 weeks of nicotinamide riboside ...

Researchers adapted the MDS-NMS tool to assess nonmotor symptoms in Huntington disease (HD), with preliminary results ...

In the first reported case of the autoinflammatory VEXAS syndrome in South Africa, J Damelin, J Jacobson, C Bam, L Pillay and ...

Benjamin Walter, MD, MBA, discusses how advances in biomarker testing and genetic characterization are informing Parkinson ...

MRD can reveal residual MDS beyond morphology, but heterogeneous clones and assay limitations complicate interpretation.

Taiho Oncology Announced Positive Phase 3 Trial Results for Azacitidine and Cedazuridine in MDS and CMML / azacitidine, cancer, cedazuridine, chronic ...

Million Research Initiative Targets New Therapies for Myelodysplastic Syndrome / blood cancers, cancer, Lore Gruenbaum, Myelodysplastic ...

Bial, an innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, is presenting 16 scientific posters at the International Congress of Parkinson’s Disease and Movement ...

Phase 3 randomized-withdrawal data in pediatrics indicated relapse in 41.9% continuing ecopipam versus 68.1% on placebo, a 53% relative relapse-risk reduction (HR, 0.50; P = .008). New analyses from ...

(TEVA), a biopharmaceutical company, reported new clinical and mechanistic data for ecopipam, an investigational selective D1 dopamine receptor antagonist being evaluated in pediatric patients with ...

A simple measurement that can be taken from any routine blood sample is attracting renewed attention as a possible prognostic ...

A single patient in Switzerland has offered hematologists and dermatologists a striking lesson in how tightly blood cancers ...